BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 19014782)

  • 1. Erythropoietin augments survival of glioma cells after radiation and temozolomide.
    Hassouna I; Sperling S; Kim E; Schulz-Schaeffer W; Rave-Fränk M; Hasselblatt M; Jelkmann W; Giese A; Ehrenreich H
    Int J Radiat Oncol Biol Phys; 2008 Nov; 72(3):927-34. PubMed ID: 19014782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Silencing erythropoietin receptor on glioma cells reinforces efficacy of temozolomide and X-rays through senescence and mitotic catastrophe.
    Pérès EA; Gérault AN; Valable S; Roussel S; Toutain J; Divoux D; Guillamo JS; Sanson M; Bernaudin M; Petit E
    Oncotarget; 2015 Feb; 6(4):2101-19. PubMed ID: 25544764
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The inhibition of proliferation and migration of glioma spheroids exposed to temozolomide is less than additive if combined with irradiation.
    Fehlauer F; Muench M; Richter E; Rades D
    Oncol Rep; 2007 Apr; 17(4):941-5. PubMed ID: 17342340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cediranib enhances control of wild type EGFR and EGFRvIII-expressing gliomas through potentiating temozolomide, but not through radiosensitization: implications for the clinic.
    Wachsberger PR; Lawrence RY; Liu Y; Xia X; Andersen B; Dicker AP
    J Neurooncol; 2011 Nov; 105(2):181-90. PubMed ID: 21516367
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Temozolomide enhances herpes simplex virus thymidine kinase/ganciclovir therapy of malignant glioma.
    Rainov NG; Fels C; Droege JW; Schäfer C; Kramm CM; Chou TC
    Cancer Gene Ther; 2001 Sep; 8(9):662-8. PubMed ID: 11593335
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Irradiation and hypoxia promote homing of haematopoietic progenitor cells towards gliomas by TGF-beta-dependent HIF-1alpha-mediated induction of CXCL12.
    Tabatabai G; Frank B; Möhle R; Weller M; Wick W
    Brain; 2006 Sep; 129(Pt 9):2426-35. PubMed ID: 16835250
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the erythropoietin receptor on glioma cells reduces tumour growth.
    Pérès EA; Valable S; Guillamo JS; Marteau L; Bernaudin JF; Roussel S; Lechapt-Zalcman E; Bernaudin M; Petit E
    Exp Cell Res; 2011 Oct; 317(16):2321-32. PubMed ID: 21749867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro responsiveness of glioma cell lines to multimodality treatment with radiotherapy, temozolomide, and epidermal growth factor receptor inhibition with cetuximab.
    Combs SE; Schulz-Ertner D; Roth W; Herold-Mende C; Debus J; Weber KJ
    Int J Radiat Oncol Biol Phys; 2007 Jul; 68(3):873-82. PubMed ID: 17544000
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survival and invasiveness of astrocytomas promoted by erythropoietin.
    Mohyeldin A; Dalgard CL; Lu H; Mcfate T; Tait AS; Patel VC; Wong K; Rushing E; Roy S; Acs G; Verma A
    J Neurosurg; 2007 Feb; 106(2):338-50. PubMed ID: 17410721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined treatment of Nimotuzumab and rapamycin is effective against temozolomide-resistant human gliomas regardless of the EGFR mutation status.
    Chong DQ; Toh XY; Ho IA; Sia KC; Newman JP; Yulyana Y; Ng WH; Lai SH; Ho MM; Dinesh N; Tham CK; Lam PY
    BMC Cancer; 2015 Apr; 15():255. PubMed ID: 25886314
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glioma cell death induced by irradiation or alkylating agent chemotherapy is independent of the intrinsic ceramide pathway.
    Gramatzki D; Herrmann C; Happold C; Becker KA; Gulbins E; Weller M; Tabatabai G
    PLoS One; 2013; 8(5):e63527. PubMed ID: 23667632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study.
    Perry JR; Bélanger K; Mason WP; Fulton D; Kavan P; Easaw J; Shields C; Kirby S; Macdonald DR; Eisenstat DD; Thiessen B; Forsyth P; Pouliot JF
    J Clin Oncol; 2010 Apr; 28(12):2051-7. PubMed ID: 20308655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. KCa3.1 channel inhibition sensitizes malignant gliomas to temozolomide treatment.
    D'Alessandro G; Grimaldi A; Chece G; Porzia A; Esposito V; Santoro A; Salvati M; Mainiero F; Ragozzino D; Di Angelantonio S; Wulff H; Catalano M; Limatola C
    Oncotarget; 2016 May; 7(21):30781-96. PubMed ID: 27096953
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergy of enediyne antibiotic lidamycin and temozolomide in suppressing glioma growth with potentiated apoptosis induction.
    Li XQ; Ouyang ZG; Zhang SH; Liu H; Shang Y; Li Y; Zhen YS
    J Neurooncol; 2014 Aug; 119(1):91-100. PubMed ID: 24842385
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhancement of glioma radiotherapy and chemotherapy response with targeted antibody therapy against death receptor 5.
    Fiveash JB; Gillespie GY; Oliver PG; Zhou T; Belenky ML; Buchsbaum DJ
    Int J Radiat Oncol Biol Phys; 2008 Jun; 71(2):507-16. PubMed ID: 18474311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metformin plus temozolomide-based chemotherapy as adjuvant treatment for WHO grade III and IV malignant gliomas.
    Soritau O; Tomuleasa C; Aldea M; Petrushev B; Susman S; Gheban D; Ioani H; Cosis A; Brie I; Irimie A; Kacso G; Florian IS
    J BUON; 2011; 16(2):282-9. PubMed ID: 21766499
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rad51 inhibition is an effective means of targeting DNA repair in glioma models and CD133+ tumor-derived cells.
    Short SC; Giampieri S; Worku M; Alcaide-German M; Sioftanos G; Bourne S; Lio KI; Shaked-Rabi M; Martindale C
    Neuro Oncol; 2011 May; 13(5):487-99. PubMed ID: 21363882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting Gliomas: Can a New Alkylating Hybrid Compound Make a Difference?
    Pinheiro R; Braga C; Santos G; Bronze MR; Perry MJ; Moreira R; Brites D; Falcão AS
    ACS Chem Neurosci; 2017 Jan; 8(1):50-59. PubMed ID: 27665765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival of human glioma cells treated with various combination of temozolomide and X-rays.
    van Rijn J; Heimans JJ; van den Berg J; van der Valk P; Slotman BJ
    Int J Radiat Oncol Biol Phys; 2000 Jun; 47(3):779-84. PubMed ID: 10837964
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Temozolomide-induced modification of the CXC chemokine network in experimental gliomas.
    Bruyère C; Mijatovic T; Lonez C; Spiegl-Kreinecker S; Berger W; Kast RE; Ruysschaert JM; Kiss R; Lefranc F
    Int J Oncol; 2011 May; 38(5):1453-64. PubMed ID: 21399866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.